AstraZeneca Bets on Chinese Innovation with a $2.1 Billion Respiratory Deal
AstraZeneca has signed a licensing agreement with Sino Biopharm for TQC3721, an investigational treatment for respiratory diseases.
Under the agreement, AstraZeneca will pay $200 million upfront and could provide up to $1.9 billion in additional milestone payments, together with royalties if development and commercial milestones are achieved.
TQC3721 is a phosphodiesterase (PDE) 3/4 inhibitor currently under development for chronic obstructive pulmonary disease (COPD). Sino Biopharm has already completed a Phase 2 study in China and reported that the combination of TQC3721 with standard therapies improved lung function compared with standard treatment and placebo.
According to Sino Biopharm, the agreement is expected to maximize the clinical and commercial potential of the investigational medicine while expanding patient access globally.
GSK Expands Its China Strategy by Handing Over Trelegy and Anoro Commercial Rights
Alongside AstraZeneca’s announcement, GSK also expanded its partnership with Sino Biopharm.
The agreement gives Sino Biopharm ownership of the commercialization rights for Trelegy and Anoro in China. The company will import, promote and distribute both respiratory medicines while recognizing the related revenue generated in the Chinese market.
Sino Biopharm described the agreement as a further step in its collaboration with GSK following a partnership announced in May to support commercialization of a hepatitis B therapy in China.
Trelegy generated global sales of £3 billion in 2025, while Anoro recorded £542 million in worldwide sales during the same period.
China Is Becoming Big Pharma's Preferred Innovation Partner
The latest announcements reflect the growing role of Chinese pharmaceutical companies in global drug development and commercialization.
AstraZeneca has remained one of the industry’s most active investors in China. The company has committed $15 billion to drug discovery, research and manufacturing activities in the country while establishing several collaborations with Chinese pharmaceutical companies, including CSPC Pharmaceutical Group.
The licensing of TQC3721 also follows increasing interest in PDE 3/4 inhibitors after Merck & Co. acquired Verona Pharma in a deal valued at approximately $10 billion.
As China Deals Multiply, Regulatory Scrutiny Is Rising Just as Fast
The two agreements also arrive during a period of increasing regulatory attention toward collaborations between Western pharmaceutical companies and Chinese biotechnology firms.
According to BioPharma Dive, nearly 100 partnerships involving U.S. or European pharmaceutical companies and Chinese counterparts have been publicly announced since the beginning of 2025. At the same time, lawmakers in the United States have proposed legislation aimed at limiting some of these collaborations while encouraging domestic biomedical research.
As pharmaceutical companies continue expanding international licensing and commercialization agreements, regulatory oversight has become an increasingly important part of the broader discussion surrounding global drug development.
As pharmaceutical partnerships increasingly cross international borders, maintaining compliant qualification and validation practices becomes essential for consistent quality and regulatory readiness throughout the product lifecycle. Learn how Zamann Pharma supports pharmaceutical teams with Qualification and Validation for GMP-Regulated Systems to build compliant, inspection-ready operations across global projects.
Source: Biopharmadive.Com